Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

More documents

Recommendations

Info

First remarks • Many of the papers (especially in the US) still rely on the Prentice Criteria for validation • Several papers are based on non randomized cohorts • Validity specific to • Disease stage • Form of summary statistic (eg: <strong>PSA</strong>-DT vs <strong>PSA</strong> response for HRPC on Taxotere) • Treatment mechanism of action (HR vs Taxotere vs Other drugs)
Review • 2 meta-analytic validations in trials of long term ADT in M0 or M1 hormone sensitive • 2 Prentice validations in randomized trials of durations of ADT adjuvant to irradiation for locally advanced PCa • Trials in HRPC – chemotherapy vs cytostatic agents
Page 1 and 2: EORTC Surrogacy Case Study: Prostat
Page 3 and 4: Prostate Specific Antigen (PSA) •
Page 5 and 6: Transition between clinical states
Page 7 and 8: Surrogate endpoint • An outcome m
Page 9 and 10: Meta-analytic validation First stag
Page 11 and 12: PSA - defined endpoints in prostate
Page 13 and 14: PSA “surrogacy” studies in the
Page 15: Published PSA surrogacy studies Col
Page 19 and 20: PSA endpoints PSA normalization A P
Page 21 and 22: PSA data (M1) Mean log(PSA) -2 0 2
Page 23 and 24: Treatment effects on OS against tre
Page 25 and 26: Prediction for a new trial - M1 •
Page 27 and 28: PSA doubling-free survival (PSA-D)
Page 29 and 30: Recommendation, M1 hormone sensitiv
Page 31 and 32: 4m vs 24m ADT adjuvant to irradiati
Page 33 and 34: PSA-DT and TTBF surrogate for PCa-s
Page 35 and 36: PSA response or PSA-V surrogate for
Page 37 and 38: Of interest… The search for the g
Page 39 and 40: Conclusions for HRPC on chemotherap
Page 41 and 42: ASCENT trial High dose Calcitriol (
Page 43 and 44: Be aware of your drug’s effect on

Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

Create successful ePaper yourself

Delete template?

Save as template?